NYSE:BHVN (USA) Also trade in: Germany

Biohaven Pharmaceutical Holding Co Ltd

$ 62.98 0 (0%)
Volume: 395,105 Avg Vol (1m): 645,910
Market Cap $: 2.80 Bil Enterprise Value $: 2.58 Bil
P/E (TTM): 0.00 P/B: 28.75
Earnings Power Value 0
Net Current Asset Value 1.79
Tangible Book 2.19
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
62.99% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
BHVN: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 2.25, Med: 10000, Max: 10000
Current: 10000
2.25
10000
Debt-to-EBITDA -0.59
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
BHVN: -0.59
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.59, Med: -0.08, Max: -0.08
Current: -0.59
-0.59
-0.08
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.53
DISTRESS
GREY
SAFE

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -201.49
ROE ranked lower than
87.77% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
BHVN: -201.49
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -879.55, Med: -599.89, Max: -201.49
Current: -201.49
-879.55
-201.49
ROA % -99.38
ROA ranked lower than
90.77% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
BHVN: -99.38
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -531.82, Med: -440.53, Max: -99.38
Current: -99.38
-531.82
-99.38
ROC (Joel Greenblatt) % -3970.31
ROC (Joel Greenblatt) ranked lower than
88.80% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
BHVN: -3970.31
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -97765.89, Med: -10571.98, Max: -3970.31
Current: -3970.31
-97765.89
-3970.31
3-Year Total EBITDA Growth Rate -183.20
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
BHVN: -102
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A

» BHVN's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:BHVN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:GERN SZSE:300255 NAS:AMRN HKSE:01681 XPAR:GNFT XKRX:102940 NAS:RGNX SZSE:300204 SZSE:000518 HKSE:06826 NAS:ATNX NAS:MRTX SZSE:300147 XKRX:005690 TSE:4593 SHSE:603896 NAS:LXRX SAU:2070 SZSE:300149 SZSE:002872
Traded in other countries 2VN.Germany
Address c/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. The company's product candidates are small molecules based on two distinct mechanistic platforms-calcitonin gene-related peptide, or CGRP, receptor antagonists and glutamate modulators-which it believes has the potential to significantly alter existing treatment approaches across a diverse set of neurological indications. The most advanced product candidate from the company's CGRP receptor antagonist platform is rimegepant, which it is developing for the acute treatment of migraine. The most advanced product candidate from glutamate modulation platform is trigriluzole.

Ratios

Current vs industry vs history
PB Ratio 28.75
PB Ratio ranked lower than
83.47% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
BHVN: 28.75
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 31.92
Current: 28.75
0
31.92
EV-to-EBIT -13.00
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
BHVN: -13
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -21.63, Med: 0, Max: 0
Current: -13
-21.63
0
EV-to-EBITDA -13.00
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
BHVN: -13
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -21.64, Med: 0, Max: 0
Current: -13
-21.64
0
Current Ratio 9.60
Current Ratio ranked higher than
64.34% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
BHVN: 9.6
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 3.03, Med: 9.6, Max: 17.84
Current: 9.6
3.03
17.84
Quick Ratio 9.60
Quick Ratio ranked higher than
64.99% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
BHVN: 9.6
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 3.03, Med: 9.6, Max: 17.84
Current: 9.6
3.03
17.84

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -40.20
3-Year Share Buyback Rate ranked lower than
100.00% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
BHVN: -40.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
N/A

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 28.76
Price-to-Tangible-Book ranked lower than
77.18% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
BHVN: 28.76
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 4.63, Med: 9.38, Max: 30.66
Current: 28.76
4.63
30.66
Earnings Yield (Joel Greenblatt) % -7.69
Earnings Yield (Greenblatt) ranked lower than
65.22% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
BHVN: -7.69
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -25.56, Med: 0, Max: 0
Current: -7.69
-25.56
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N